10 FAQs About Semaglutide

Semaglutide is a medication originally developed to treat type 2 diabetes but has also been found to be effective for weight loss in non diabetics. It mimics a hormone that targets areas of the brain involved in appetite regulation, leading to reduced hunger and calorie intake.

Side effects, such as nausea, vomiting, and diarrhea, typically diminish within a few weeks of starting treatment. Continuous communication with your healthcare provider is crucial to manage any persistent side effects.

Semaglutide works by imitating the effects of a hormone called GLP-1 (glucagon-like peptide-1), which is naturally produced in our bodies after eating. This hormone plays a key role in regulating blood sugar levels and slowing down gastric emptying, which contributes to a feeling of fullness and satisfaction after meals. By activating GLP-1 receptors in the brain, semaglutide effectively reduces appetite and calorie intake, leading to weight loss in individuals.

Most individuals begin to notice a decrease in their appetite within the first few weeks of starting semaglutide treatment. However, the full appetite-suppressing effects of the medication can take longer to manifest, varying from person to person. It’s important to follow the prescribed dosage and maintain regular contact with your healthcare provider to monitor progress and make adjustments if necessary.

The duration of semaglutide treatment for weight loss varies by individual. After achieving the desired weight, some may continue at a maintenance dose; however, a long-term plan should be developed with your healthcare provider.

Weight loss results can be observed as early as 2–4 weeks after starting the treatment, with significant results often seen within 6 months.

Weight loss with semaglutide can vary widely among individuals. On average, patients might see a 5-10% reduction in body weight over 3 months, but outcomes can differ based on diet, exercise, and adherence to the medication.

Nausea is a common side effect because semaglutide slows gastric emptying, making you feel fuller, longer. This reaction typically diminishes as your body adjusts to the medication.

Semaglutide is administered through subcutaneous injections, usually in the abdomen, thigh, or upper arm. Proper technique and rotation of injection sites are recommended. Your healthcare provider will teach you how to inject the medication so that you can do it safely and comfortably at home.

Discontinuation of semaglutide may lead to weight regain in some people. Therefore, discontinuing the medication should be done under medical guidance, alongside lifestyle changes to maintain weight loss.

Semaglutide and tirzepatide are both GLP-1 receptor agonists, meaning they mimic the effects of the naturally occurring hormone GLP-1 in the body. Semaglutide is approved by the FDA for use as a weight loss drug in non-diabetics. Tirzepatide is currently only approved for use in individuals with type 2 diabetes.